INSTI Major Mutations: G1405 • Q148H

INSTI Accessory Mutations: None

NSTEACCESSORY MUCADOIIS.

Drug resistance interpretation: IN

IN Other Mutations: E11D • A21T • D25E • S119G • T122I • T125A • V201I • I203M • T218S • L234I • D253E • D278E

Integrase Strand Transfer Inhibitors

bictegravir (BIC) Intermediate Resistance
cabotegravir (CAB) High-Level Resistance
dolutegravir (DTG) Intermediate Resistance
elvitegravir (EVG) High-Level Resistance
raltegravir (RAL) High-Level Resistance

IN comments

Majo

- G1405/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility.
- Q148H/K/R are nonpolymorphic mutations reported in persons receiving RAL, EVG, CAB, and DTG. They nearly always occur in combination with G140A/S or E138K. In this setting they are associated with near complete resistance to RAL and EVG, high-levels of reduction in CAB susceptibility, and low-to-intermediate reductions in DTG and BIC susceptibility.
- There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily.

Mutation scoring: IN

Drug resistance mutation scores of INSTI-

Download CSV

G1405 10 10 10 30 30 G1405+Q148H 10 20 10 0 0 Q148H 25 30 25 60 60	brug residunce mutation scores or instr.				Download CSV	
G1405+Q148H 10 20 10 0 0 Q148H 25 30 25 60 60	Rule	BIC ÷	CAB ≑	DTG ÷	EVG ‡	RAL :
Q148H 25 30 25 60 60	G1405	10	10	10	30	30
	G1405+Q148H	10	20	10	0	0
Total 45 60 45 90 90	Q148H	25	30	25	60	60
	Total	45	60	45	90	90

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)